Quantum Genomics (Alternext - FR0011648971 - ALQGC), a biopharmaceutical company with the mission of developing new therapies for unsatisfied medical needs in the field of cardiovascular diseases, today announces the publication of its second shareholder newsletter.
Contents of this second issue:
- A word from Lionel Ségard, Chairman and Chief Executive Officer of Quantum Genomics : “Since June, we have announced major progress in our various research programmes for cardiovascular diseases.”
- Recent news : Initiation of a joint laboratory with INSERM
- Zoom : Proceedings of the Phase IIa clinical trial in hypertension
- Portrait : Dr. Catherine Llorens-Cortes
- Shareholder guide
The shareholder newsletter is available on the company's website at www.quantum-genomics.com, in the Shareholder letters section of the Investors tab.
Chairman & Chief Executive Officer
+33 1 85 34 77 77
CFO – Investor Relations
+33 1 85 34 77 75
ACTUS finance & communication (Europe)
+33 1 53 67 36 73 / firstname.lastname@example.org
The Ruth Group (U.S.)
Lee Roth / Kirsten Thomas
Investor / Public Relations
+1 646-536-7012 / +1 508-280-6592
|ABOUT QUANTUM GENOMICS
Quantum Genomics is a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, especially hypertension and heart failure.
The Company is developing a new therapeutic approach based on BAPAI (Brain Aminopeptidase A Inhibition). This is the result of more than 20 years of academic research in the laboratories of the Collège de France, INSERM, CNRS and the University of Paris Descartes.
Quantum Genomics is listed on the Alternext market in Paris (ISIN code FR0011648971, Ticker ALQGC).
The Company has offices in Paris, France, and New York, NY, USA. For more information, please visit www.quantum-genomics.com.
Powered by Actusnews Wire (press release services) ©